Sign inJoin waitlistJoin the waitlist

Dai Chihara

Associate Professor, Lymphoma and Myeloma · University of Texas M D Anderson Cancer Center

Credentials: · · · · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2017–2020
Medical Oncology
2018–2020
Internal Medicine
University of New Mexico-Main Campus
2016–2018
Hematology
Aichi Cancer Center Hospital
2008–2010
Otsu Red Cross Hospital
2004–2008
Doctor of Medicine
2000–2004

Research

Differences in incidence and trends of haematological malignancies in Japan and the United States
British Journal of Haematology · 2014 · First of 10 authors · 276 citations
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Nature Medicine · 2023 · 216 citations
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
Annals of Oncology · 2015 · 156 citations

Loretta Nastoupil
40 papers · 6 as a fellow
Christopher Flowers
39 papers
Jason Westin
34 papers
Sattva Neelapu
30 papers
Luis Fayad
28 papers
YO
Yasuhiro Oki
28 papers · 3 as a fellow
Paolo Strati
21 papers
MF
Michelle Fanale
17 papers
NF
Nathan Fowler
17 papers
Maria Rodriguez
16 papers
Ranjit Nair
16 papers
Sairah Ahmed
15 papers

Clinical trials

PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCL
Principal investigator · Not yet recruiting
M.D. Anderson Cancer Center
2027–2029
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2027–2030
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2031
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2025–2032